AIM
LXRX icon

Alambic Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Alambic Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,500
Closed -$165K – 534
2016
Q2 		$165K Buy
+11,500
New +$156K 0.04% 472

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alambic Investment Management's LXRX Position: Q3 2016 in Review

Alambic Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2016, closing a stake of 11,500 shares — an estimated $165K sold.

Alambic Investment Management first reported a position in LXRX in Q2 2016 and held it in 1 quarter. The position peaked at $165K in Q2 2016. 142 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

  • Alambic Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Alambic Investment Management sold 11,500 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $165K.
  • Alambic Investment Management first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Alambic Investment Management's Lexicon Pharmaceuticals position peaked at $165K in Q2 2016.
  • 142 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Alambic Investment Management's 13F filing for Q3 2016, filed 28 Oct 2016.